The NCPA survey found that 51% of respondents say they are strongly considering not stocking the drugs because of the potential underwater reimbursements from pharmacy benefit managers.
Dasatinib is a kinase inhibitor used to treat certain types of leukemia in both adults and children 1 year of age and older, including cases where previous treatment were not effective or tolerated.